Protalix Biotherapeutics (PLX)
:PLX
Earnings Data
Report Date
May 08, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.05Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably EU regulatory approval for a differentiated 4-week Elfabrio dosing regimen), a material $25 million milestone that meaningfully improves near-term liquidity, and active progression of pipeline assets (PRX-115 enrollment). These positive developments were balanced against higher R&D spending (up 51%), a 2025 net loss of $6.6 million versus prior-year income, increased cost of goods sold, and near-term operational and reimbursement timing risks across EU countries and uncertainty around U.S. label changes. Overall, the company appears well positioned financially and clinically going into 2026 due primarily to the milestone and partner execution, although investors should watch cash burn, R&D spending, and timing of commercial rollout.Company Guidance
European Commission Approval of Elfabrio 4-Week Dosing
European Commission approved a 2 mg/kg every 4-week dosing regimen for Elfabrio for adults stable on enzyme replacement therapy, strengthening competitive positioning in the EU and differentiating Elfabrio versus competitors.
Regulatory Milestone and Near-Term Cash Inflow
The EU approval triggered a $25.0 million regulatory milestone payment from partner Chiesi, supporting a projected cash balance of approximately $50.0 million by early April 2026 (from $30.3 million at 12/31/2025).
2026 Revenue Guidance — Significant Growth Expected
Full-year 2026 total revenue guidance of $78.0 million to $83.0 million includes the $25.0 million milestone; expected Chiesi-related revenues of $33.0 million to $35.0 million (projected growth of more than 50% year-over-year) and Elelyso revenues of $20.0 million to $23.0 million.
Commercial Execution by Chiesi Driving Patient Growth
Chiesi reported consistent increases in patient numbers across the U.S. and key ex-U.S. markets, successfully growing both treatment-naive and switch patients and enhancing Elfabrio uptake and long-term market trajectory (Fabry market projected to reach ~$3.4 billion by 2030).
Advancing Clinical Pipeline — PRX-115 Enrollment
PRX-115 Phase II RELEASE study is actively enrolling with first patients randomized; topline results anticipated in the second half of 2027. Company positions PRX-115 as a potential best-in-class therapy for uncontrolled gout with differentiated dosing possibilities.
Pipeline Expansion and Partnerships
Protalix is expanding its rare renal pipeline (PRX-119, long-acting DNase) and collaborating on RNA-based programs with Secarna, indicating multiple development avenues beyond current commercial products.
Improved Cost Structure Signals
SG&A expenses declined slightly to $11.7 million in 2025 mainly due to lower share-based compensation; interest expense reduced following full repayment of secured convertible notes in 2024, partially offsetting FX-related financial expense.
PLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 18, 2026 | $2.79 | $2.21 | -20.79% |
Nov 13, 2025 | $2.14 | $1.93 | -9.81% |
Aug 14, 2025 | $1.61 | $1.52 | -5.59% |
May 09, 2025 | $2.89 | $1.72 | -40.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Protalix Biotherapeutics (PLX) report earnings?
Protalix Biotherapeutics (PLX) is schdueled to report earning on May 08, 2026, TBA (Confirmed).
What is Protalix Biotherapeutics (PLX) earnings time?
Protalix Biotherapeutics (PLX) earnings time is at May 08, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLX EPS forecast?
PLX EPS forecast for the fiscal quarter 2026 (Q1) is -0.01.